Skip to main content
Erschienen in: AIDS and Behavior 5/2012

01.07.2012 | Original Paper

Supporting Study Product Use and Accuracy in Self-Report in the iPrEx Study: Next Step Counseling and Neutral Assessment

verfasst von: K. R. Amico, Vanessa McMahan, Pedro Goicochea, Lorena Vargas, Julia L. Marcus, Robert M. Grant, Albert Liu

Erschienen in: AIDS and Behavior | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

The recent successes of biomedical HIV prevention approaches have sparked considerable debate over the scalability, feasibility, and acceptability of pre-exposure prophylaxis (PrEP) as a widespread prevention strategy for men who have sex with men and trans-gender. Anticipated difficulties with PrEP adherence and concerns about resources required to best support it have tempered enthusiasm of PrEP demonstration projects and roll-out. While no evidence-based approach for supporting PrEP use is presently available, a number of approaches have been developed in the context of double-blind, randomized, placebo-controlled trials of PrEP that can provide guidance in moving forward with real world support of open label PrEP use. We present the development, implementation and evaluation of feasibility and acceptability of next-step counseling (NSC) and neutral assessment (NA), the adherence support and promotion of accurate reporting approaches used in the late phases of the iPrEx study. Evaluation of the approach from the perspective of implementers of over 15,000 NSC sessions in seven different countries with almost 2,000 iPrEx participants provided support for NSC, its brevity (averaging ~14 min per follow-up session) and overall acceptability and feasibility. NA also was generally well supported, with a majority of study staff believing this approach was feasible and acceptable; however, lower acceptability for certain aspects of NA was noted amongst staff reporting NA was different from their previous interview approach. Quantitative and qualitative data gathered from implementers were used to make modifications for supporting PrEP use in the open-label extension of iPrEx.
Fußnoten
1
The identification of processes and procedures thought to enhance or deter either product use or accurate reporting was heavily influenced by our adaptation of behavioral models for these behaviors, which is presented separately below.
 
Literatur
1.
Zurück zum Zitat Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS. 2010;24:621–35.PubMedCrossRef Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS. 2010;24:621–35.PubMedCrossRef
2.
Zurück zum Zitat Abdool KQ, Abdool KSS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–74.CrossRef Abdool KQ, Abdool KSS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–74.CrossRef
3.
Zurück zum Zitat Grant RM, Lama JR, Anderson PL, McMahan V, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. NEJM. 2010. doi:10.1056/NEJMoa1011205. Grant RM, Lama JR, Anderson PL, McMahan V, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. NEJM. 2010. doi:10.​1056/​NEJMoa1011205.
4.
Zurück zum Zitat Baeten J, Celum C, on behalf of Partners PrEP Study Team. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the partners PrEP study. In: 6th international AIDS Society conference on HIV pathogenesis treatment and prevention, Rome; 2011. Baeten J, Celum C, on behalf of Partners PrEP Study Team. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the partners PrEP study. In: 6th international AIDS Society conference on HIV pathogenesis treatment and prevention, Rome; 2011.
5.
Zurück zum Zitat Thigpen MC, Kebaabetswa PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study.In: 6th international AIDS society conference on HIV pathogenesis treatment and prevention. Rome; 2011. Thigpen MC, Kebaabetswa PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study.In: 6th international AIDS society conference on HIV pathogenesis treatment and prevention. Rome; 2011.
6.
Zurück zum Zitat Leibowitz AA, Parker KB, Rotheram-Borus MJ. A US policy perspective on oral preexporsure prophylaxis for HIV. AJPH. 2011;101(6):982–5.CrossRef Leibowitz AA, Parker KB, Rotheram-Borus MJ. A US policy perspective on oral preexporsure prophylaxis for HIV. AJPH. 2011;101(6):982–5.CrossRef
7.
Zurück zum Zitat Amico KR, Liu A, McMahan V et al. Adherence indicators and pre-exposure prophylaxis (PrEP) drug levels in the iPrEx study.In: 18th conference on retroviruses and opportunistic infections (CROI). Boston, US; 2011. Amico KR, Liu A, McMahan V et al. Adherence indicators and pre-exposure prophylaxis (PrEP) drug levels in the iPrEx study.In: 18th conference on retroviruses and opportunistic infections (CROI). Boston, US; 2011.
8.
Zurück zum Zitat Anderson PL, Lama JR, Buchbinder S et al. Interpreting detection rates of intracellular emtricitabine–triphosphate (FTC-TP) and tenofovir-diphosphate (TFV-DP) in the iPrEx trial.In: 18th conference on retroviruses and opportunistic infections (CROI). Boston, US; 2011. Anderson PL, Lama JR, Buchbinder S et al. Interpreting detection rates of intracellular emtricitabine–triphosphate (FTC-TP) and tenofovir-diphosphate (TFV-DP) in the iPrEx trial.In: 18th conference on retroviruses and opportunistic infections (CROI). Boston, US; 2011.
9.
Zurück zum Zitat Grant R, Lama J, Glidden D et al. Pre-exposure chemprophylaxis for prevention of HIV among trans-women and MSM: iPREx study.In: 18th conference on retroviruses and opportunistic infections (CROI). Boston, US; 2011. Grant R, Lama J, Glidden D et al. Pre-exposure chemprophylaxis for prevention of HIV among trans-women and MSM: iPREx study.In: 18th conference on retroviruses and opportunistic infections (CROI). Boston, US; 2011.
10.
Zurück zum Zitat Vargas L, Amico KR, Goicochea P et al. Pill-taking support and assessment: Self reported perceptions of participants in a PrEP trial. International Association of Physicians in Adherence Care Conference. Miami, USA, 2010. [abstract # 62257]. Vargas L, Amico KR, Goicochea P et al. Pill-taking support and assessment: Self reported perceptions of participants in a PrEP trial. International Association of Physicians in Adherence Care Conference. Miami, USA, 2010. [abstract # 62257].
11.
Zurück zum Zitat Bartholomew LK, Parcel GS, Kok G, Gottlieb NH: planning health promotion programs. An Intervention Mapping approach. 2nd edn. San Francisco, CA, Jossey-Bass; 2006. Bartholomew LK, Parcel GS, Kok G, Gottlieb NH: planning health promotion programs. An Intervention Mapping approach. 2nd edn. San Francisco, CA, Jossey-Bass; 2006.
12.
Zurück zum Zitat Kok G, Schaalma H, Ruiter RA, van Empelen P, Brug J. Intervention mapping: protocol for applying health psychology theory to prevention programmes. J Health Psychol. 2004;9(1):85–98.PubMedCrossRef Kok G, Schaalma H, Ruiter RA, van Empelen P, Brug J. Intervention mapping: protocol for applying health psychology theory to prevention programmes. J Health Psychol. 2004;9(1):85–98.PubMedCrossRef
13.
Zurück zum Zitat US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), and Center for Devices and Radiological Health (CDRH). Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009, Dec. Accessed 27 Feb 2012 from http://www.ispor.org/workpaper/FDA%20PRO%20Guidance.pdf. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), and Center for Devices and Radiological Health (CDRH). Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009, Dec. Accessed 27 Feb 2012 from http://​www.​ispor.​org/​workpaper/​FDA%20​PRO%20​Guidance.​pdf.
14.
Zurück zum Zitat Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring medication adherence in research. AIDS and Behav. 2012. doi:10.1007/s10461-012-0172-7. Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring medication adherence in research. AIDS and Behav. 2012. doi:10.​1007/​s10461-012-0172-7.
15.
Zurück zum Zitat Fisher JD, Fisher WA, Amico KR, Harman JJ. An information-motivation-behavioral skills model of adherence to antiretroviral therapy. Health Psychol. 2006;25(4):462–73.PubMedCrossRef Fisher JD, Fisher WA, Amico KR, Harman JJ. An information-motivation-behavioral skills model of adherence to antiretroviral therapy. Health Psychol. 2006;25(4):462–73.PubMedCrossRef
16.
Zurück zum Zitat Fisher JD, Amico KR, Fisher WA, Harman JJ. The information-motivation-behavioral skills model of antiretroviral adherence and its applications. Curr HIV/AIDS Rep. 2008;5(4):193–203.PubMedCrossRef Fisher JD, Amico KR, Fisher WA, Harman JJ. The information-motivation-behavioral skills model of antiretroviral adherence and its applications. Curr HIV/AIDS Rep. 2008;5(4):193–203.PubMedCrossRef
17.
Zurück zum Zitat Wilson IB, Carter AE, Berg KM. Improving the self-report of HIV antiretroviral medication adherence: is the glass half full or half empty? Curr HIV/AIDS Rep. 2009;6(4):177–86.PubMedCrossRef Wilson IB, Carter AE, Berg KM. Improving the self-report of HIV antiretroviral medication adherence: is the glass half full or half empty? Curr HIV/AIDS Rep. 2009;6(4):177–86.PubMedCrossRef
18.
Zurück zum Zitat Fisher JD, Fisher WA, Cornman DH, Amico KR, Bryan A, Friedland GH. Clinician-delivered Intervention during routine clinical care reduces risky sexual behavior of HIV infected patients. J Acquir Immune Defic Syndr. 2006;41(1):44–52.PubMedCrossRef Fisher JD, Fisher WA, Cornman DH, Amico KR, Bryan A, Friedland GH. Clinician-delivered Intervention during routine clinical care reduces risky sexual behavior of HIV infected patients. J Acquir Immune Defic Syndr. 2006;41(1):44–52.PubMedCrossRef
19.
Zurück zum Zitat Rollnick S, Miller WR, Butler CC. Motivational Interviewing in Health Care: Helping Patients Change Behavior. New York: Guilford Press; 2008. Rollnick S, Miller WR, Butler CC. Motivational Interviewing in Health Care: Helping Patients Change Behavior. New York: Guilford Press; 2008.
20.
Zurück zum Zitat Fisher JD, Fisher WA. Changing AIDS-risk behavior. Psych Bull. 1992;111(3):455–74.CrossRef Fisher JD, Fisher WA. Changing AIDS-risk behavior. Psych Bull. 1992;111(3):455–74.CrossRef
22.
Zurück zum Zitat Golub SA, Operario D, Gorbach PM. Pre-exposure prophylaxis state of the science: empirical analogies for research and implementation. Curr HIV/AIDS Rep. 2010;7(4):201–9.PubMedCrossRef Golub SA, Operario D, Gorbach PM. Pre-exposure prophylaxis state of the science: empirical analogies for research and implementation. Curr HIV/AIDS Rep. 2010;7(4):201–9.PubMedCrossRef
23.
Zurück zum Zitat Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk US populations: current considerations in light of new findings. AIDS Pt Care STDs. 2011;25(2):63–71.CrossRef Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk US populations: current considerations in light of new findings. AIDS Pt Care STDs. 2011;25(2):63–71.CrossRef
24.
Zurück zum Zitat Stirratt MJ, Gordon CM. Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep. 2008;5(4):186–92.PubMedCrossRef Stirratt MJ, Gordon CM. Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep. 2008;5(4):186–92.PubMedCrossRef
25.
Zurück zum Zitat Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J AIDS. 2006;41(3):285–97. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J AIDS. 2006;41(3):285–97.
27.
Zurück zum Zitat de Bruin M, Viechtbauer W, Schaalma HP, Kok G, Abraham C, Hospers HJ. Standard care impacts intervention effects in HAART adherence RCTs: a meta-analysis. Arch Intern Med. 2010;170(3):240–50.PubMedCrossRef de Bruin M, Viechtbauer W, Schaalma HP, Kok G, Abraham C, Hospers HJ. Standard care impacts intervention effects in HAART adherence RCTs: a meta-analysis. Arch Intern Med. 2010;170(3):240–50.PubMedCrossRef
28.
Zurück zum Zitat Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load––a meta-analytic review of randomized controlled trials. J AIDS. 2006;43:S23–35. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load––a meta-analytic review of randomized controlled trials. J AIDS. 2006;43:S23–35.
Metadaten
Titel
Supporting Study Product Use and Accuracy in Self-Report in the iPrEx Study: Next Step Counseling and Neutral Assessment
verfasst von
K. R. Amico
Vanessa McMahan
Pedro Goicochea
Lorena Vargas
Julia L. Marcus
Robert M. Grant
Albert Liu
Publikationsdatum
01.07.2012
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 5/2012
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-012-0182-5

Weitere Artikel der Ausgabe 5/2012

AIDS and Behavior 5/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.